Weight Variations during First-Line Systemic Treatment of Metastatic Non-Small Cell Lung Cancer: New Paradigms from Real-World Data.
Introduction: In studies, weight loss is strongly associated with outcomes in metastatic non-squamous cell lung cancer (mNSCLC). This work examines weight variations in first-line treatment, exploring their mechanisms based on treatment type, age, sex, weight loss, and excess weight before treatment...
| Published in: | Oncology Vol. 104; no. 8; pp. 891 - 900 |
|---|---|
| Main Authors: | , , , , , , |
| Format: | research tables/charts Journal Article |
| Published: |
Karger AG
2026
|
| Online Access: | View this record in EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=195416406&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 195416406 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 00302414 NK2 jtl: Oncology issn: 00302414 maglogo: N pubinfo: dt: 2026 vid: 104 iid: 8 pid: 2485 pub: Karger AG artinfo: ui: 195416406 193004699 195416406 195416406 10.1159/000550347 195416406 ppf: 891 ppct: 9 formats: tig: atl: Weight Variations during First-Line Systemic Treatment of Metastatic Non-Small Cell Lung Cancer: New Paradigms from Real-World Data. aug: au: Gravian, Alexandre Pagès, Arnaud Tarabay, Anthony Delaye, Virginie Scottée, Florian Merad, Mansouria Antoun, Sami affil: Service de Médecine Aigüe en Cancérologie, Gustave Roussy, Villejuif, France sug: subj: Carcinoma, Non-Small-Cell Lung Drug Therapy Neoplasm Metastasis Drug Therapy Neoadjuvant Therapy Body Weight Changes Evaluation Age Factors Sex Factors Weight Loss Obesity Human Retrospective Design Record Review Cancer Patients Psychosocial Factors Immune Checkpoint Inhibitors Treatment Duration Chemotherapy, Cancer Body Mass Index Nutritional Status Descriptive Statistics Nonexperimental Studies Descriptive Research Cancer Care Facilities France Anthropometry Chi Square Test Wilcoxon Rank Sum Test Kruskal-Wallis Test Data Analysis Software ab: Introduction: In studies, weight loss is strongly associated with outcomes in metastatic non-squamous cell lung cancer (mNSCLC). This work examines weight variations in first-line treatment, exploring their mechanisms based on treatment type, age, sex, weight loss, and excess weight before treatment. Methods: A retrospective analysis was conducted on patients undergoing first-line treatment. Weight was recorded at four points: before treatment (Wbe), day 1 of treatment (Wd1), 3 months into immune checkpoint inhibitors (ICIs) treatment or maintenance (W3mo), and at progression diagnosis (Wpro). Results: Among patients (n = 198), 47% received chemotherapy (CT) with ICIs, 26% CT alone, and 27% ICIs alone. At Wd1, 32% were overweight/obese (body mass index kg/m2) (BMI ≥ 25). Weight loss ≥ 5% before treatment was observed in 37%. Mean (SD) weight variations between Wd1 and W3mo were −1.1% (4.6) (CT), −0.2% (7.1) (CT+ICIs), and +0.4% (7.7) (ICIs alone) (p = 0.52). Patients older than 70 compared to ≤70 lost more weight between Wd1 and Wpro (−4.7% vs. −0.4%) (p = 0.019). Patients with pre-treatment weight loss ≥ 5% compared to those without weight loss stabilized or gained weight during treatment (+2.1% vs. −1.5%) (p = 0.009). Patients with BMI ≥ 25 lost more weight during treatment than those with BMI <25 (−1.4% vs. +0.8%) (p = 0.024). Conclusion: Weight variations did not differ significantly across treatment types. Older patients are nutritionally more vulnerable. Pre-treatment significant weight loss ≥ 5% patients stabilized or gained weight during treatment, unlike those without initial weight loss. Pre-treatment weight loss in first-line mNSCLC supports, rather than contraindicates, cancer therapy. Higher BMI was associated with greater weight loss during treatment. pubtype: Academic Journal doctype: research tables/charts Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|